Alexandre Mutchmore, Mathieu Labossière, Michel Cauchon, Marc-Émile Plourde, Luc Lanthier
{"title":"对于心血管事件高风险的2型糖尿病患者,与安慰剂相比,口服西马鲁肽是否能降低主要不良心血管事件的风险,它是否安全?]","authors":"Alexandre Mutchmore, Mathieu Labossière, Michel Cauchon, Marc-Émile Plourde, Luc Lanthier","doi":"10.1016/j.revmed.2025.05.010","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[In patients with type 2 diabetes at high risk of cardiovascular events, does oral semaglutide decrease the risk of major adverse cardiovascular events compared to placebo, and is it safe?]\",\"authors\":\"Alexandre Mutchmore, Mathieu Labossière, Michel Cauchon, Marc-Émile Plourde, Luc Lanthier\",\"doi\":\"10.1016/j.revmed.2025.05.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":94122,\"journal\":{\"name\":\"La Revue de medecine interne\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"La Revue de medecine interne\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.revmed.2025.05.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue de medecine interne","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.revmed.2025.05.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[In patients with type 2 diabetes at high risk of cardiovascular events, does oral semaglutide decrease the risk of major adverse cardiovascular events compared to placebo, and is it safe?]